|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Cash and non-interest bearing deposits in other financial institutions | ||||||||||||||||||||
| Interest bearing deposits in other financial institutions | ||||||||||||||||||||
| Federal funds sold | ||||||||||||||||||||
| Total cash and cash equivalents | ||||||||||||||||||||
| Certificates of deposit in other financial institutions | ||||||||||||||||||||
| Securities available-for-sale | ||||||||||||||||||||
| Loans held-for-sale | ||||||||||||||||||||
| Loans receivable, net of deferred fees and costs | ||||||||||||||||||||
| Less: Allowance for credit losses | ||||||||||||||||||||
| Net loans receivable | ||||||||||||||||||||
| Federal Home Loan Bank stock | ||||||||||||||||||||
| Accrued interest receivable | ||||||||||||||||||||
| Foreclosed real estate | ||||||||||||||||||||
| Premises and equipment | ||||||||||||||||||||
| Cash value of bank owned life insurance | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Other intangible assets | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||||||||||||||
| Deposits: | ||||||||||||||||||||
| Non-interest bearing | ||||||||||||||||||||
| Interest bearing | ||||||||||||||||||||
| Total | ||||||||||||||||||||
| Repurchase agreements | ||||||||||||||||||||
| Federal funds purchased and repurchase agreements | ||||||||||||||||||||
| Borrowed funds | ||||||||||||||||||||
| Accrued expenses and other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders' Equity: | ||||||||||||||||||||
| Preferred stock, no par or stated value; 10,000,000 shares authorized, none outstanding | ||||||||||||||||||||
| Common stock, no par or stated value; 10,000,000 shares authorized; shares issued and outstanding: June 30, 2026 - 4,333,002 December 31, 2025 - 4,326,747 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Total stockholders' equity | ||||||||||||||||||||
| Total liabilities and stockholders' equity | ||||||||||||||||||||
Loading...
